2023
In vivo synaptic density loss correlates with impaired functional and related structural connectivity in Alzheimer’s disease
Zhang J, Wang J, Xu X, You Z, Huang Q, Huang Y, Guo Q, Guan Y, Zhao J, Liu J, Xu W, Deng Y, Xie F, Li B. In vivo synaptic density loss correlates with impaired functional and related structural connectivity in Alzheimer’s disease. Cerebrovascular And Brain Metabolism Reviews 2023, 43: 977-988. PMID: 36718002, PMCID: PMC10196742, DOI: 10.1177/0271678x231153730.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseCognitionCognitive DysfunctionHumansMagnetic Resonance ImagingPyridinesConceptsMiddle frontal gyrusAlzheimer's diseaseSynaptic densityMild cognitive impairmentSynapse lossCognitive impairmentCaudal middle frontal gyrusFunctional connectivityLower synaptic densityMajor pathological changesRight insular cortexStructural connectivity alterationsRight middle frontal gyrusWhite matter tractsSynaptic alterationsBilateral cortexConnectivity alterationsInsular cortexAD groupPathological changesConnectivity dysfunctionCognitive declineCognitive functionFunctional MRIDisease
2001
Synthesis of potent and selective dopamine D4 antagonists as candidate radioligands
Huang Y, Kegeles L, Bae S, Hwang D, Roth B, Savage J, Laruelle M. Synthesis of potent and selective dopamine D4 antagonists as candidate radioligands. Bioorganic & Medicinal Chemistry Letters 2001, 11: 1375-1377. PMID: 11378358, DOI: 10.1016/s0960-894x(01)00241-4.Peer-Reviewed Original ResearchDifferential Occupancy of Somatodendritic and Postsynaptic 5HT1A Receptors by Pindolol: A Dose-Occupancy Study with [11C]WAY 100635 and Positron Emission Tomography in Humans
Martinez D, Hwang D, Mawlawi O, Slifstein M, Kent J, Simpson N, Parsey R, Hashimoto T, Huang Y, Shinn A, Van Heertum R, Abi-Dargham A, Caltabiano S, Malizia A, Cowley H, Mann J, Laruelle M. Differential Occupancy of Somatodendritic and Postsynaptic 5HT1A Receptors by Pindolol: A Dose-Occupancy Study with [11C]WAY 100635 and Positron Emission Tomography in Humans. Neuropsychopharmacology 2001, 24: 209-229. PMID: 11166513, DOI: 10.1016/s0893-133x(00)00187-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsBrainHumansKineticsMagnetic Resonance ImagingMaleMood DisordersPindololPiperazinesPyridinesRaphe NucleiReceptors, NeurotransmitterReceptors, SerotoninReceptors, Serotonin, 5-HT1Selective Serotonin Reuptake InhibitorsSynaptic TransmissionTomography, Emission-ComputedConceptsDorsal raphe nucleusPositron emission tomographyClinical studiesSelective serotonin reuptake inhibitor (SSRI) therapyPlacebo-controlled clinical studySerotonin reuptake inhibitor therapyEmission tomographyAbility of pindololPindolol augmentationAntidepressant therapyAntidepressant treatmentClinical responseInhibitor therapyRaphe nucleusScan 3Scan 4Therapeutic effectHealthy volunteersScan 2Vivo selectivityPindololAutoreceptorsSSRIsTherapyInconsistent results